Results 91 to 100 of about 202,297 (260)

Hypersensitivity pneumonitis: Main features characterization in a Portuguese cohort.

open access: yesPulmonology, 2020
Hypersensitivity pneumonitis (HP) is an interstitial lung disease (ILD) which varies in prevalence across the world, depending on disease definition, diagnostic methods, exposure type and intensity, geographical environments, agricultural and industrial ...
Vanessa Santos   +13 more
semanticscholar   +1 more source

Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany [PDF]

open access: yes, 2009
Background: Diffuse parenchymal lung diseases (DPLD) in children represent a rare and heterogeneous group of chronic pulmonary disorders. Despite substantial advances in genetics and pathomechanisms, these often lethal diseases are still under-diagnosed.
Matthias Griese   +20 more
core   +3 more sources

Machine learning methods for predicting adverse drug events: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo   +8 more
wiley   +1 more source

Hypersensitivity pneumonitis: Antigen diversity and disease implications.

open access: yesPulmonology, 2019
Hypersensitivity pneumonitis (HP) is an immune-mediated syndrome triggered by inhalation of a wide variety of allergens, to which an individual has previously been sensitized. More than 200 agents responsible for the disease have already been identified;
R. Nogueira   +6 more
semanticscholar   +1 more source

A major genetic determinant of autoimmune diseases is associated with the presence of autoantibodies in hypersensitivity pneumonitis

open access: yesEuropean Respiratory Journal, 2020
Background Hypersensitivity pneumonitis is an immune-mediated disease triggered by exposure to organic particles in susceptible individuals. It has been reported that a subgroup of patients with hypersensitivity pneumonitis develops autoantibodies with ...
I. Buendía-Roldán   +8 more
semanticscholar   +1 more source

Late‐Onset Mesalazine‐Induced Eosinophilic Pneumonitis Presenting as Non‐Resolving Pneumonia: A Diagnostic Pitfall in Ulcerative Colitis

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Mesalazine is widely used in the management of ulcerative colitis and is generally well tolerated. Rarely, it can cause eosinophilic pneumonitis, a potentially serious form of drug‐induced lung injury that often mimics infection. We report a 24‐year‐old male with longstanding ulcerative colitis on mesalazine therapy for 2 years and 4 months ...
Siraj Nasim   +3 more
wiley   +1 more source

Einfluss der Art der Materialgewinnung auf die Diagnosefindung in der Lungenpathologie [PDF]

open access: yes, 2019
Das Ziel der Arbeit ist die Darstellung der Möglichkeiten der Kryobiopsien für die Diagnostik von Lungenerkrankungen und Pleuraerkrankungen. Es wurde zunächst gezeigt, dass die transbronchialen Kryobiopsien einen deutlichen morphologischen Unterschied ...
Griff, Sergej
core   +1 more source

Secondhand smoke from electronic cigarette resulting in hypersensitivity pneumonitis

open access: yesBMJ Case Reports, 2020
Cases of vaping-induced lung injury have increased in the USA, resulting in a heterogeneous collection of pneumonitis patterns in persons who used electronic cigarettes.
P. Galiatsatos   +5 more
semanticscholar   +1 more source

Heat Therapy: Targeting Health, Disease, and Disability

open access: yesComprehensive Physiology, Volume 16, Issue 1, February 2026.
The predominance of evidence suggests heat therapy has an impact on all aspects of health and performance, but the drivers of that improvement, the extent to which they are improved, and the specific populations in which improvements manifest are far from completely understood.
Rauchelle E. Richey   +5 more
wiley   +1 more source

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial [PDF]

open access: yes, 2017
Background: Pirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which
Behr, Jürgen   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy